UNSPSC 51332874: Thiopropazate dihydrochloride

This classification denotes a phenothiazine with the molecular formula C23H28ClN3O2S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K5E7BGM8X, chemically known as 2-(4-(3-(2-chlorophenothiazin-10-yl)propyl)piperazin-1-yl)ethyl acetate dihydrochloride, but more generally known as thiopropazate dihydrochloride, which bears US NIH Compound Identifier 67416. European Medicines Agency schedules thiopropazate dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10982MIG.

Most nations, for tariff purposes, schedule thiopropazate dihydrochloride under HS 29343090. SMILES: CC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)CL.CL.CL.

UNSPSC 51332874 Thiopropazate dihydrochloride is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little direct alignment with thiopropazate procurement itself. Instead, the code appears tagged to broader pharmaceutical and therapeutic supply solicitations that include generic multi-source drugs, over-the-counter products, naloxone, and drug deactivation systems. State and local issuing bodies using this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The actual procurement work involves establishing supply contracts for pharmaceutical products with defined National Drug Codes, managing vendor relationships through authorized wholesalers, and sourcing both branded and generic therapeutics for public health initiatives including opioid response and community health programs.

Recent activity shows solicitations primarily from Florida county government and Texas and Minnesota state health agencies. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for managing pharmacy benefit delivery outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with vendor proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors in MMCAP procurements must maintain relationships with authorized wholesalers, comply with FDA and Drug Supply Chain Security Act requirements, and accept a 3 percent administrative fee on all contract purchases.